This article was originally published in The Gray Sheet
Executive SummaryAdopts stockholders rights plan in response to "increased levels of acquisition activity in the healthcare industry." The company says it is not aware of any proposed acquisition of the firm. The rights, which are exercisable 10 days after the acquisition of or tender offer for 15% or more of Target's common stock, entitle shareholders (other than the potential acquiring entity) to purchase stock, and in some cases cash or property, with a market value of twice the exercise price. The rights also allow shareholders to purchase one one-thousandth of a share of the company's Series A participating preferred stock for $135
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.